Scarica l'app Stockscreener
34.74
0.14%
-0.05
Dopo l'orario di chiusura:
34.74
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$34.79
Aprire:
$34.94
Volume 24 ore:
884.45K
Relative Volume:
0.45
Capitalizzazione di mercato:
$5.94B
Reddito:
-
Utile/perdita netta:
$-354.30M
Rapporto P/E:
-18.06
EPS:
-1.9234
Flusso di cassa netto:
$-266.00M
1 W Prestazione:
-5.16%
1M Prestazione:
-5.98%
6M Prestazione:
+134.41%
1 anno Prestazione:
+597.59%
Intervallo 1D:
$34.47
$35.40
Intervallo di 1 settimana:
$34.47
$37.51
Portata 52W:
$4.55
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Nome
Cogent Biosciences Inc
Settore
Industria
Telefono
617-945-5576
Indirizzo
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
34.74 | 5.94B | 0 | -354.30M | -266.00M | -1.9234 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.34B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.96B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.51B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.89B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2025-11-10 | Aggiornamento | Stifel | Hold → Buy |
| 2025-11-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-10-16 | Iniziato | Stifel | Hold |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-11 | Downgrade | Needham | Buy → Hold |
| 2024-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Iniziato | Citigroup | Buy |
| 2023-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-12-08 | Iniziato | JP Morgan | Overweight |
| 2023-04-28 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-27 | Ripresa | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-06-28 | Iniziato | Guggenheim | Buy |
| 2021-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-09 | Ripresa | Jefferies | Buy |
| 2020-12-23 | Iniziato | Piper Sandler | Overweight |
| 2020-10-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
Pier Capital LLC Buys Shares of 46,260 Cogent Biosciences, Inc. $COGT - MarketBeat
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT) - The Globe and Mail
Cogent Biosciences, Inc. $COGT Shares Purchased by Vanguard Group Inc. - MarketBeat
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Cogent Biosciences (COGT) Valuation After Wider Q1 Loss And Bezuclastinib Regulatory Progress - Yahoo Finance
A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $45 to $55 - Moomoo
A Look At Cogent Biosciences (COGT) Valuation After First Quarter Earnings Loss And Strong One Year Share Price Run - Sahm
H.C. Wainwright raises Cogent stock price target to $55 on cash runway - Investing.com UK
Understanding the Setup: (COGT) and Scalable Risk - Stock Traders Daily
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results - Investing News Network
Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cogent Biosciences (NASDAQ:COGT) Releases Earnings Results - MarketBeat
Cogent Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bezuclastinib NDAs and cash into 2028 at Cogent Biosciences (NASDAQ: COGT) - Stock Titan
Cogent Biosciences 1Q 2026: Net loss $(97.4)M, EPS $(0.53) — 10-Q Summary - TradingView
Biotechnology company Cogent Biosciences, Inc.'s latest financial data shows that as of the end of the first quarter of 2026, the company held a total of $866.4 million in cash and cash equivalents. - Bitget
Cogent Biosciences (COGT) boosts cash to fund bezuclastinib NDAs and launch plans - Stock Titan
Cogent Biosciences Q1 net loss widens on higher expenses - TradingView
Cogent plans two bezuclastinib launches, says cash lasts into 2028 - Stock Titan
BRIEF-Cogent Biosciences Q1 Income From Operations USD -103.607 Million - TradingView
MSN Money - MSN
Pictet Asset Management Holding SA Boosts Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
COGT SEC FilingsCogent Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cogent Biosciences Inc (NASDAQ:COGT) Shows Bullish Technical Breakout Setup with High Scores - ChartMill
Systemic Mastocytosis (SM) Treatment Market 2026-2035: - GlobeNewswire
Systemic Mastocytosis (SM) Treatment Market 2026-2035: Industry to More Than Double in Size, Led by Sanofi, AdvaCare Pharma, and Cogent Biosciences - Yahoo Finance
Teachers Retirement System of The State of Kentucky Invests $1.33 Million in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Drop in Short Interest - MarketBeat
Cogent Biosciences (COGT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Cogent Biosciences prices equity offering and 1.625% convertible senior notes - MSN
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - MSN
A Look At Cogent Biosciences (COGT) Valuation After New KRAS And ErbB2 Data At AACR 2026 - Sahm
The Technical Signals Behind (COGT) That Institutions Follow - Stock Traders Daily
[ARS] Cogent Biosciences, Inc. SEC Filing - Stock Titan
Cogent Biosciences (NASDAQ: COGT) details 2026 proxy, pivotal bezuclastinib wins and $901M cash - Stock Titan
COGT (Cogent Biosciences Inc.) reports wider Q4 2025 loss than consensus analyst estimates, with shares dipping 0.36 percent in today's trading.Market Buzz Alerts - Xã Thanh Hà
Cogent Biosciences reports selective pan-KRAS inhibitor CGT-1263 - BioWorld News
Cogent Biosciences (NASDAQ:COGT) Shares Cross Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors at the 2026 American Society of Clinical Oncology Annual Meeting - Investing News Network
Cogent’s positive tumor trial lands an oral presentation at ASCO - Stock Titan
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - marketscreener.com
Cogent Biosciences Announces Oral Presentation of Positive - GlobeNewswire
Analysts Expect Breakeven For Cogent Biosciences, Inc. (NASDAQ:COGT) Before Long - 富途牛牛
HC Wainwright & Co. Reiterates Cogent Biosciences (COGT) Buy Recommendation - MSN
Cogent Biosciences (COGT): Billionaire Stan Druckenmiller admires upside potential of this stock - MSN
Cogent Bio (COGT) Stock: Invest or Wait? (+2.93%) 2026-04-18Fast Rising Stocks - Xã Thanh Hà
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Sahm
Is AACR 2026 KRAS and ErbB2 Data Altering The Investment Case For Cogent Biosciences (COGT)? - Sahm
Cogent Biosciences (COGT) Showcases Promising Data at AACR Annua - GuruFocus
Cogent Biosciences Inc Azioni (COGT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
11.97%
3.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):